Dr. Kamal R. Chemali, MD

Dr. Chemali practices at Sentara Norfolk General Hospital in Norfolk, Virginia, part of Sentara Health.

Dr. Chemali's NPI, 1265474795, was assigned on June 11, 2006. Dr. Chemali holds Virginia license 0101250018.

Dr. Chemali's primary practice is Sentara Norfolk General Hospital, at 600 Gresham Dr, Norfolk, VA 23507 in Norfolk City. The practice phone is (757) 388-3000.

Dr. Chemali's primary practice is Sentara Norfolk General Hospital in Norfolk, Virginia, part of Sentara Health. Dr. Chemali is also affiliated with University Hospitals Cleveland Medical Center. The medical group on file is University Hospitals Medical Practices. Dmand AI also links Dr. Chemali to 1 more hospital outpatient department, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Chemali practices, 3 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Chemali's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dmand AI has Dr. Chemali's licenses on file in 2 states: Virginia and Ohio.

CMS data shows 241 Medicare services from Dr. Chemali across 11 procedure codes in 2024, for 112 Medicare patients. Medicare paid $12,132 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 112 Medicare patients who saw Dr. Chemali in 2024. The largest group is 65 to 74, with 58 patients. 75% of them have high cholesterol, and 72% have high blood pressure. 11% are also on Medicaid. Their average risk score is 1.36, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Chemali's median patient age at 52, with 66% women.

In 2024, Dr. Chemali wrote 85 Medicare Part D claims for 15 patients. 73% of them were for generic drugs. CMS names the drug for 44 of them, across 3 drugs with 11 or more claims each, at $138,142 in total drug cost. In 2023, CMS named 44 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Chemali for performance year 2024, reported as part of a group. Dr. Chemali accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Chemali as offering telehealth. CMS counts 12 procedures of skin biopsy by Dr. Chemali, more than 60% of the clinicians it reports for that procedure.

Dmand AI links Dr. Chemali to 1 clinical trial. Conditions studied include dopamine beta hydroxylase deficiency and Pure Autonomic Failure. Open Payments lists research payments to Dr. Chemali that name 1 trial.

CMS Open Payments shows 66 general payments to Dr. Chemali from 16 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 76% of the total. CSL Behring paid the most, $12,038. It also lists 3 research payments totaling $1,385 in 2019, naming 1 clinical trial.